 therapy fluconazole flucytosine murine cryptococcal meningitis possible beneficial effects combined therapy fluconazole flucytosine treatment cryptococcal meningitis immunocompromised host therapy fluconazole flucytosine experimental murine model BALB/c athymic nu/nu mice CFU Cryptococcus mortality studies treatment postinfection days fluconazole mg/kg body weight day flucytosine drugs Noble agar control therapy mortality controls single-drug regimens broad range doses Quantitative determinations CFU brain tissue burden neoformans mice receiving therapy results therapy fluconazole flucytosine superior single-drug therapy